mocetinostat + docetaxel

Mocetinostat (MGCD0103) is an orally available, isotype-selective benzamide inhibitor of histone deacetylases (HDACs), primarily targeting HDAC1, HDAC2, HDAC3 (class I), and HDAC11 (class IV). It modulates aberrant gene expression and restores normal growth control in malignancies by increasing histone acetylation, leading to cell cycle arrest and apoptosis. Mocetinostat has been investigated in clinical trials for various cancers including follicular lymphoma, Hodgkin's lymphoma, acute myeloid leukemia, and solid tumors[4][6][8]. Docetaxel is a semisynthetic taxane antineoplastic agent that promotes microtubule assembly while inhibiting their depolymerization. This disrupts mitotic spindle function during cell division, resulting in inhibition of mitosis and induction of apoptosis. Docetaxel is approved for the treatment of several cancers including breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head/neck cancer[1][2][3]. The combination of mocetinostat (MGCD0103) with docetaxel has been explored in clinical studies as a potential therapy for advanced solid tumors due to their complementary mechanisms—epigenetic modulation by mocetinostat and cytotoxicity via microtubule stabilization by docetaxel.

Brand names

TaxotereDocefrezDocivyx

Other names

MGCD0103 + docetaxelmocetinostat + docetaxel